drugset
drugset / Trial / NCT06001151

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

NCT06001151 ↗

Phase 2 Recruiting 49 enrolled Qian Chu Akeso Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.

Timeline

Start
2023-08-07
Primary completion
2025-08-31
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg —
Background Carboplatin Small molecule 5 unknown —
Background Pemetrexed Small molecule 500 mg/m2 —

Indications

non-small cell lung carcinoma